About MAPP BIOPHARMACEUTICAL, INC.
Mapp Biopharmaceutical, Inc. develops novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. The company collaborates with BARDA on the development of therapeutics for viral diseases such as Marburg virus.
Development of monoclonal antibody therapeuticsResearch in infectious disease prevention and treatmentCollaboration with BARDA on viral disease therapeutics
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMEN | Department of Health and Human Services | $110.9M | |
| DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | Department of Health and Human Services | $16.4M | |
| DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | Department of Health and Human Services | $3.0M | |
| PROCUREMENT OF HUMAN DERIVED MONOCLONAL ANTIBODIES AND ANTIGENS | Department of Defense | $20K | |
| HUMAN-DERIVED MONOCLONAL ANTIBODIES AND RECOMBINANT ANTIGENS | Department of Defense | $60K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to MAPP BIOPHARMACEUTICAL, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.